8 articles
Via News read the risk-factors section of every S&P 500 filing that names generative AI. The top fear, in 44%, isn’t hallucination or cost — it’s being out-competed. Companies aren’t afraid of the machine; they’re afraid of the rival with the better machine.
Via News read every S&P 500 10-K back to 2019. AI mentions went from 100 companies to 446. But the revealing shift is where they put it: “generative AI” moved from the strategy section in 2023 to the risk-factors section by 2024, and stayed there.
Via News searched annual 10-K filings back to 2019. “Generative AI” appears essentially nowhere before 2023, then explodes — the cleanest marker yet of the moment AI stopped being an experiment and became infrastructure, measured in companies’ own words.
MindWalk Holdings filed a new patent on July 15 extending its HYFT biological-pattern technology, while NVIDIA deepens lab partnerships with Thermo Fisher and Eli Lilly. Denmark's Novo Nordisk closed its cell therapy unit and licensed a Parkinson's asset to an AI platform instead, signaling European pharma is renting US-built AI infrastructure rather than owning it.
NVIDIA is positioning its BioNeMo platform as the foundational compute and software layer for pharmaceutical research worldwide, drawing comparisons to how cloud giants reshaped enterprise technology. With anchor partnerships from Eli Lilly and Thermo Fisher Scientific, the strategy mirrors NVIDIA's earlier dominance in AI infrastructure — this time targeting the multi-trillion-dollar global drug development industry.
NVIDIA is aggressively expanding its BioNeMo platform into pharmaceutical and biotech research worldwide, securing partnerships with Thermo Fisher Scientific and Eli Lilly as major indicators of institutional commitment. The move mirrors how CUDA became indispensable for GPU computing, and signals a structural shift in how biological research is financed and conducted globally. A parallel ecosystem of specialized AI biotech companies is emerging alongside NVIDIA, echoing the early cloud era's dy
NVIDIA is quietly replicating the AWS infrastructure playbook inside the pharmaceutical industry, positioning its BioNeMo platform as the default computational layer for drug discovery worldwide. Partnerships with Eli Lilly and Thermo Fisher Scientific signal institutional credibility, while a growing ecosystem of AI biotech firms from the US to Europe is building atop BioNeMo — raising questions about who will control the underlying architecture of global medicine.
Planet Labs has announced plans to launch two prototype satellites under Project SunCatcher in early 2027, each equipped with Google Tensor Processing Units capable of running artificial intelligence workloads directly in orbit. The initiative, backed by Google R&D funding and its Gemini team, marks a significant shift in how satellite data is processed globally — eliminating hours of latency between an event on the ground and actionable intelligence reaching decision-makers worldwide. The devel